Abstract: Novel 3-halo-2,2-disubstituted propanenitriles of formula ##STR1## wherein Z represents bromo or chloro and A, together with the carbon atom to which it is attached, represents a 5,6 or 7 membered saturated carbocyclic or heterocyclic ring, are useful as intermediates for preparing substituted pyrimido[1,2-a]indoles. The intermediates can be prepared by a novel process which comprises condensing a 2,2-disubstituted ethanenitrile with a dihalomethane in the presence of a non-nucleophilic strong base.

Abstract: Novel quinazoline and cinnoline derivatives having the formula ##STR1## (wherein one of A and B is CH and the other one of A and B is N; X.sub.1 is halogen or CF.sub.3 and X.sub.3 is one of the groups II, III, IV or V ##STR2## where Q is lower alkylene; R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are independently lower alkyl or R.sub.2 and R.sub.3 are a divalent radical such that HNR.sub.2 R.sub.3 is a secondary cyclic amine with 5 to 7 ring atoms; R.sub.4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I (where A, B and X.sub.1 are defined above and X.sub.3 is OH).

Abstract: 4-Aminoquioline derivatives having the formula ##STR1## and their pharmaceutically acceptable salts where X.sub.1 is halogen or trifluoromethyl and X.sub.2 is a group having the formula--NR.sub.1 --Q--N--R.sub.4 (II)where R.sub.1 is hydrogen or lower alkyl; Q is lower alkylene; R.sub.4 is lower alkyl and the ring illustrated is a piperidine or pyrrolidine ring optionally substituted by lower alkyl, exhibit anti-hypertensive activity. Corresponding compounds where R.sub.4 is replaced by latent lower alkyl, a protecting group or hydrogen may be used as intermediates.

Abstract: Novel quinazoline and cinnoline derivatives having the formula ##STR1## (wherein one of A and B is CH and the other one of A and B is N; X.sub.1 is halogen or CF.sub.3 and X.sub.3 is one of the groups II, III, IV or V ##STR2## where Q is lower alkylene; R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are independently lower alkyl or R.sub.2 and R.sub.3 are a divalent radical such that HNR.sub.2 R.sub.3 is a secondary cyclic amine with 5 to 7 ring atoms; R.sub.4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I (where A, B and X.sub.1 are defined above and X.sub.3 is OH).

Abstract: A solid pharmaceutical composition comprising anhydrous cholestyramine, 0.6 to 1.7 parts by weight of low viscosity grade alginic acid/sodium alginate per weight of cholestyramine, the low viscosity grade alginic acid/sodium alginate having 0 to 75% of the acid groups neutralized, 0.1 to 0.3 parts by weight of citric acid per weight of sodium alginate, and sufficient sodium carbonate or bicarbonate mixtures thereof to neutralize the acid groups of the alginic and citric acids. The compositions may be used in the treatment of conditions associated with duodeno-gastric reflux of bile into the stomach.